Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | M6223 |
| Trade Name | |
| Synonyms | M-6223|M 6223 |
| Drug Descriptions |
M6223 targets and binds to TIGIT on immune cells, including tumor-infiltrating lymphocytes, and prevents its interaction with CD112 and CD155, thereby leading to enhanced interaction of CD112 and CD155 with CD226 expressed on natural killer and CD8 T+ cells, which may lead to the activation of anti-tumor immune responses (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C173891 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Avelumab + M6223 | Avelumab M6223 | 0 | 1 |
| Bintrafusp alfa + M6223 | Bintrafusp alfa M6223 | 0 | 1 |
| M6223 | M6223 | 0 | 1 |